{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:26:59Z","timestamp":1792016819923,"version":"4.4.0"},"reference-count":177,"publisher":"Frontiers Media SA","funder":[{"DOI":"10.13039\/501100002283","name":"Alzheimer\u2019s Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002283","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000320","name":"Alzheimer\u2019s Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000320","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000304","name":"Parkinson\u2019s UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000304","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2015.00236","type":"journal-article","created":{"date-parts":[[2015,11,16]],"date-time":"2015-11-16T01:00:50Z","timestamp":1447635650000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":105,"title":["Blood-Based Proteomic Biomarkers of Alzheimer\u2019s Disease Pathology"],"prefix":"10.3389","volume":"6","author":[{"given":"Alison L.","family":"Baird","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Westwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Lovestone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2015,11,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jalz.2012.11.007","article-title":"The global prevalence of dementia: a systematic review and metaanalysis","volume":"9","author":"Prince","year":"2013","journal-title":"Alzheimers Dement"},{"key":"B2","volume-title":"World Alzheimer Report 2010: The Global Economic Impact of Dementia","author":"Wimo","year":"2010"},{"key":"B3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1136\/jnnp.66.2.137","article-title":"The cholinergic hypothesis of Alzheimer\u2019s disease: a review of progress","volume":"66","author":"Francis","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/ana.22248","article-title":"Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease","volume":"69","author":"Villemagne","year":"2011","journal-title":"Ann Neurol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"a006213","DOI":"10.1101\/cshperspect.a006213","article-title":"Brain imaging in Alzheimer disease","volume":"2","author":"Johnson","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1373\/clinchem.2013.202937","article-title":"Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-beta(1-42) and tau proteins as Alzheimer disease biomarkers","volume":"59","author":"Kang","year":"2013","journal-title":"Clin Chem"},{"key":"B7","doi-asserted-by":"publisher","first-page":"271","DOI":"10.4061\/2010\/635053","article-title":"Standardization of assay procedures for analysis of the CSF biomarkers amyloid beta((1-42)), tau, and phosphorylated tau in Alzheimer\u2019s disease: report of an international workshop","volume":"35","author":"Teunissen","year":"2010","journal-title":"Int J Alzheimers Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","article-title":"Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers","volume":"12","author":"Jack","year":"2013","journal-title":"Lancet Neurol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1001\/jamaneurol.2014.4829","article-title":"Nonlinear association between cerebrospinal fluid and florbetapir F-18 beta-amyloid measures across the spectrum of Alzheimer disease","volume":"72","author":"Toledo","year":"2015","journal-title":"JAMA Neurol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1074\/mcp.R200007-MCP200","article-title":"The human plasma proteome","volume":"1","author":"Anderson","year":"2002","journal-title":"Mol Cell Proteomics"},{"key":"B11","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.neuron.2014.12.032","article-title":"Blood-brain barrier breakdown in the aging human hippocampus","volume":"85","author":"Montagne","year":"2015","journal-title":"Neuron"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.1002\/elps.200406068","article-title":"Electrophoretic separation of amyloid beta peptides in plasma","volume":"25","author":"Lewczuk","year":"2004","journal-title":"Electrophoresis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/prca.201400120","article-title":"Quantitation with chemical tagging reagents in biomarker studies","volume":"9","author":"Westbrook","year":"2015","journal-title":"Proteomics Clin Appl"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1074\/mcp.M300031-MCP200","article-title":"Characterization of the low molecular weight human serum proteome","volume":"2","author":"Tirumalai","year":"2003","journal-title":"Mol Cell Proteomics"},{"key":"B15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.euprot.2013.09.001","article-title":"Comparison of peptide and protein fractionation methods in proteomics","volume":"1","author":"Mostovenko","year":"2013","journal-title":"EuPA Open Proteom"},{"key":"B16","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s10585-008-9152-8","article-title":"Serum proteome analysis for profiling protein markers associated with carcinogenesis and lymph node metastasis in nasopharyngeal carcinoma","volume":"25","author":"Liao","year":"2008","journal-title":"Clin Exp Metastasis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"191","DOI":"10.4172\/jpb.1000139","article-title":"Serpine 1 links obesity and diabetes: a pilot study","volume":"3","author":"Kaur","year":"2010","journal-title":"J Proteomics Bioinform"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1021\/pr2002098","article-title":"Rapid verification of candidate serological biomarkers using gel-based, label-free multiple reaction monitoring","volume":"10","author":"Tang","year":"2011","journal-title":"J Proteome Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1373\/clinchem.2009.130518","article-title":"Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease","volume":"56","author":"Mulder","year":"2010","journal-title":"Clin Chem"},{"key":"B20","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3233\/JAD-2010-1221","article-title":"Alzheimer\u2019s disease and the amyloid-beta peptide","volume":"19","author":"Murphy","year":"2010","journal-title":"J Alzheimers Dis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.1073\/pnas.82.12.4245","article-title":"Amyloid plaque core protein in Alzheimer disease and Down syndrome","volume":"82","author":"Masters","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B22","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1006\/exnr.1999.7085","article-title":"The levels of soluble versus insoluble brain Abeta distinguish Alzheimer\u2019s disease from normal and pathologic aging","volume":"158","author":"Wang","year":"1999","journal-title":"Exp Neurol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3233\/JAD-2011-101977","article-title":"Meta-analysis of plasma amyloid-beta levels in Alzheimer\u2019s disease","volume":"26","author":"Song","year":"2011","journal-title":"J Alzheimers Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1001\/archneurol.2011.1841","article-title":"Plasma amyloid-beta as a predictor of dementia and cognitive decline: a systematic review and meta-analysis","volume":"69","author":"Koyama","year":"2012","journal-title":"Arch Neurol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.3233\/JAD-2010-090249","article-title":"Plasma amyloid-beta as a biomarker in Alzheimer\u2019s disease: the AIBL study of aging","volume":"20","author":"Lui","year":"2010","journal-title":"J Alzheimers Dis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.neulet.2007.09.058","article-title":"The influence of diagnosis, intra- and inter-person variability on serum and plasma Abeta levels","volume":"428","author":"Abdullah","year":"2007","journal-title":"Neurosci Lett"},{"key":"B27","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1001\/archneur.65.6.776","article-title":"Plasma amyloid beta-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease","volume":"65","author":"Locascio","year":"2008","journal-title":"Arch Neurol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jalz.2012.12.006","article-title":"Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer\u2019s disease","volume":"10","author":"Rembach","year":"2014","journal-title":"Alzheimers Dement"},{"key":"B29","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jns.2011.03.005","article-title":"The relationship of plasma Abeta levels to dementia in aging individuals with mild cognitive impairment","volume":"305","author":"Fei","year":"2011","journal-title":"J Neurol Sci"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2006.09.002","article-title":"Conversion from cognitive health to mild cognitive impairment and Alzheimer\u2019s disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine","volume":"29","author":"Blasko","year":"2008","journal-title":"Neurobiol Aging"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1212\/01.WNL.0000091890.32140.8F","article-title":"Plasma A[beta]40 and A[beta]42 and Alzheimer\u2019s disease: relation to age, mortality, and risk","volume":"61","author":"Mayeux","year":"2003","journal-title":"Neurology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1097\/00019442-200510000-00012","article-title":"Selective reductions in plasma Abeta 1-42 in healthy elderly subjects during longitudinal follow-up: a preliminary report","volume":"13","author":"Pomara","year":"2005","journal-title":"Am J Geriatr Psychiatry"},{"key":"B33","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/gps.4053","article-title":"The efficacy of plasma biomarkers in early diagnosis of Alzheimer\u2019s disease","volume":"29","author":"Wang","year":"2014","journal-title":"Int J Geriatr Psychiatry"},{"key":"B34","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.exger.2009.06.003","article-title":"Validation of Alzheimer\u2019s disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer\u2019s disease neuroimaging initiative (E-ADNI)","volume":"44","author":"Buerger","year":"2009","journal-title":"Exp Gerontol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jalz.2014.07.001","article-title":"Plasma amyloid-beta and risk of Alzheimer\u2019s disease in the Framingham Heart Study","volume":"11","author":"Chouraki","year":"2015","journal-title":"Alzheimers Dement"},{"key":"B36","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1001\/archneur.64.3.354","article-title":"Association of low plasma Abeta42\/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease","volume":"64","author":"Graff-Radford","year":"2007","journal-title":"Arch Neurol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S1474-4422(06)70501-4","article-title":"Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study","volume":"5","author":"van Oijen","year":"2006","journal-title":"Lancet Neurol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1046\/j.1471-4159.1996.67020880.x","article-title":"Fate of cerebrospinal fluid-borne amyloid beta-peptide: rapid clearance into blood and appreciable accumulation by cerebral arteries","volume":"67","author":"Ghersi-Egea","year":"1996","journal-title":"J Neurochem"},{"key":"B39","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1002\/ana.410380413","article-title":"Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer\u2019s disease","volume":"38","author":"Motter","year":"1995","journal-title":"Ann Neurol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/S0304-3940(01)01754-2","article-title":"Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease","volume":"304","author":"Mehta","year":"2001","journal-title":"Neurosci Lett"},{"key":"B41","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.neuint.2009.08.006","article-title":"No correlation between time-linked plasma and CSF Abeta levels","volume":"55","author":"Le Bastard","year":"2009","journal-title":"Neurochem Int"},{"key":"B42","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","article-title":"Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease","volume":"367","author":"Bateman","year":"2012","journal-title":"N Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/380168a0","article-title":"Beta-amyloid-mediated vasoactivity and vascular endothelial damage","volume":"380","author":"Thomas","year":"1996","journal-title":"Nature"},{"key":"B44","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/ana.20318","article-title":"AD lesions and infarcts in demented and non-demented Japanese-American men","volume":"57","author":"Petrovitch","year":"2005","journal-title":"Ann Neurol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1097\/NEN.0b013e31803d3ae4","article-title":"Plasma Abeta levels do not reflect brain Abeta levels","volume":"66","author":"Freeman","year":"2007","journal-title":"J Neuropathol Exp Neurol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1212\/WNL.0b013e318224afb7","article-title":"Plasma Abeta and PET PiB binding are inversely related in mild cognitive impairment","volume":"77","author":"Devanand","year":"2011","journal-title":"Neurology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1021\/cn500101j","article-title":"Plasma Abeta but not tau is related to brain PiB retention in early Alzheimer\u2019s disease","volume":"5","author":"Tzen","year":"2014","journal-title":"ACS Chem Neurosci"},{"key":"B48","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2183\/pjab.90.353","article-title":"Novel plasma biomarker surrogating cerebral amyloid deposition","volume":"90","author":"Kaneko","year":"2014","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1001\/archneurol.2012.18107","article-title":"Beta-amyloid dynamics in human plasma","volume":"69","author":"Huang","year":"2012","journal-title":"Arch Neurol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1006\/bbrc.1999.0552","article-title":"High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer\u2019s disease","volume":"257","author":"Kuo","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"B51","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13195-014-0056-3","article-title":"Association between cell-bound blood amyloid-beta(1-40) levels and hippocampus volume","volume":"6","author":"Sotolongo-Grau","year":"2014","journal-title":"Alzheimers Res Ther"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.2174\/156720512804142967","article-title":"New assay for old markers-plasma beta amyloid of mild cognitive impairment and Alzheimer\u2019s disease","volume":"9","author":"Chiu","year":"2012","journal-title":"Curr Alzheimer Res"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e64990","DOI":"10.1371\/journal.pone.0064990","article-title":"An enzyme-generated fragment of tau measured in serum shows an inverse correlation to cognitive function","volume":"8","author":"Henriksen","year":"2013","journal-title":"PLoS One"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.3233\/JAD-140984","article-title":"Relationship between serum levels of tau fragments and clinical progression of Alzheimer\u2019s disease","volume":"43","author":"Henriksen","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"B55","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/alzrt163","article-title":"Plasma tau levels in Alzheimer\u2019s disease","volume":"5","author":"Zetterberg","year":"2013","journal-title":"Alzheimers Res Ther"},{"key":"B56","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nbt.1641","article-title":"Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations","volume":"28","author":"Rissin","year":"2010","journal-title":"Nat Biotechnol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1002\/hbm.22390","article-title":"Plasma tau as a window to the brain-negative associations with brain volume and memory function in mild cognitive impairment and early Alzheimer\u2019s disease","volume":"35","author":"Chiu","year":"2014","journal-title":"Hum Brain Mapp"},{"key":"B58","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.neurobiolaging.2006.05.016","article-title":"Microvascular injury and blood-brain barrier leakage in Alzheimer\u2019s disease","volume":"28","author":"Zipser","year":"2007","journal-title":"Neurobiol Aging"},{"key":"B59","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/ana.410320110","article-title":"An abnormality of plasma amyloid protein precursor in Alzheimer\u2019s disease","volume":"32","author":"Bush","year":"1992","journal-title":"Ann Neurol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1038\/nm1196-1230","article-title":"Serum levels of the iron binding protein p97 are elevated in Alzheimer\u2019s disease","volume":"2","author":"Kennard","year":"1996","journal-title":"Nat Med"},{"key":"B61","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0304-3940(98)00960-4","article-title":"19\/20 kDa low molecular weight serum protein pattern: a novel potential biochemical prognostic marker for different types of dementia","volume":"260","author":"Lombardi","year":"1999","journal-title":"Neurosci Lett"},{"key":"B62","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S0009-9120(00)00185-5","article-title":"Human kallikrein 6 as a biomarker of Alzheimer\u2019s disease","volume":"33","author":"Diamandis","year":"2000","journal-title":"Clin Biochem"},{"key":"B63","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1034\/j.1600-0404.2000.09011.x","article-title":"Serum and cerebrospinal fluid cystatin C levels in vascular and Alzheimer\u2019s dementia","volume":"101","author":"Kalman","year":"2000","journal-title":"Acta Neurol Scand"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1002\/(SICI)1522-2683(20000501)21:91832::AID-ELPS18323.0.CO;2-7","article-title":"Analysis of blood plasma proteins in patients with Alzheimer\u2019s disease by two-dimensional electrophoresis, sequence homology and immunodetection","volume":"21","author":"Ueno","year":"2000","journal-title":"Electrophoresis"},{"key":"B65","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/00002093-200101000-00007","article-title":"Alpha-1-antichymotrypsin and oxidative stress in the peripheral blood from patients with probable Alzheimer disease: a short-term longitudinal study","volume":"15","author":"Licastro","year":"2001","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"B66","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/ana.10265","article-title":"Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study","volume":"52","author":"Schmidt","year":"2002","journal-title":"Ann Neurol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1016\/j.exger.2004.07.007","article-title":"Increased plasma levels of soluble CD40, together with the decrease of TGF beta 1, as possible differential markers of Alzheimer disease","volume":"39","author":"Mocali","year":"2004","journal-title":"Exp Gerontol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/pmic.200300495","article-title":"Mining biomarkers in human sera using proteomic tools","volume":"4","author":"Zhang","year":"2004","journal-title":"Proteomics"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1161\/01.STR.0000189721.31432.26","article-title":"Fibrinogen is associated with an increased risk of Alzheimer disease and vascular dementia","volume":"36","author":"van Oijen","year":"2005","journal-title":"Stroke"},{"key":"B70","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1159\/000090676","article-title":"Proteomic identification of lower apolipoprotein A-I in Alzheimer\u2019s disease","volume":"21","author":"Liu","year":"2006","journal-title":"Dement Geriatr Cogn Disord"},{"key":"B71","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1159\/000107700","article-title":"Peripheral inflammatory cytokines as biomarkers in Alzheimer\u2019s disease and mild cognitive impairment","volume":"4","author":"Guerreiro","year":"2007","journal-title":"Neurodegener Dis"},{"key":"B72","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/prca.200600684","article-title":"Proteomics analysis of plasma for potential biomarkers in the diagnosis of Alzheimer\u2019s disease","volume":"1","author":"Liao","year":"2007","journal-title":"Proteomics Clin Appl"},{"key":"B73","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1155\/2007\/432190","article-title":"The diagnostic role of serum inflammatory and soluble proteins on dementia subtypes: correlation with cognitive and functional decline","volume":"18","author":"Ozturk","year":"2007","journal-title":"Behav Neurol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"585","DOI":"10.3233\/JAD-2010-100279","article-title":"Plasma gelsolin is decreased and correlates with rate of decline in Alzheimer\u2019s disease","volume":"21","author":"Guntert","year":"2010","journal-title":"J Alzheimers Dis"},{"key":"B75","doi-asserted-by":"publisher","first-page":"409","DOI":"10.2174\/156720510791383813","article-title":"Macrophage colony-stimulating factor (M-CSF) in plasma and CSF of patients with mild cognitive impairment and Alzheimer\u2019s disease","volume":"7","author":"Laske","year":"2010","journal-title":"Curr Alzheimer Res"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.3233\/JAD-2010-1303","article-title":"The heme degradation pathway is a promising serum biomarker source for the early detection of Alzheimer\u2019s disease","volume":"19","author":"Mueller","year":"2010","journal-title":"J Alzheimers Dis"},{"key":"B77","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3233\/JAD-2011-102145","article-title":"Human serum transthyretin levels correlate inversely with Alzheimer\u2019s disease","volume":"25","author":"Han","year":"2011","journal-title":"J Alzheimers Dis"},{"key":"B78","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1021\/pr200270z","article-title":"Serum levels of pregnancy zone protein are elevated in presymptomatic Alzheimer\u2019s disease","volume":"10","author":"Ijsselstijn","year":"2011","journal-title":"J Proteome Res"},{"key":"B79","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/j.1468-1331.2010.03273.x","article-title":"Brain-specific fatty acid-binding protein is elevated in serum of patients with dementia-related diseases","volume":"18","author":"Teunissen","year":"2011","journal-title":"Eur J Neurol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s00702-012-0781-3","article-title":"Multidimensional plasma protein separation technique for identification of potential Alzheimer\u2019s disease plasma biomarkers: a pilot study","volume":"119","author":"Henkel","year":"2012","journal-title":"J Neural Transm"},{"key":"B81","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1002\/jnr.23122","article-title":"Characterization of plasma beta-secretase (BACE1) activity and soluble amyloid precursor proteins as potential biomarkers for Alzheimer\u2019s disease","volume":"90","author":"Wu","year":"2012","journal-title":"J Neurosci Res"},{"key":"B82","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1016\/j.jprot.2012.04.017","article-title":"Activity-dependent neuroprotector homeobox protein: a candidate protein identified in serum as diagnostic biomarker for Alzheimer\u2019s disease","volume":"75","author":"Yang","year":"2012","journal-title":"J Proteomics"},{"key":"B83","first-page":"49","article-title":"Inflammatory markers in Alzheimer\u2019s disease and vascular dementia","volume":"113","author":"Androsova","year":"2013","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"key":"B84","doi-asserted-by":"publisher","first-page":"e75091","DOI":"10.1371\/journal.pone.0075091","article-title":"Increased neurofilament light chain blood levels in neurodegenerative neurological diseases","volume":"8","author":"Gaiottino","year":"2013","journal-title":"PLoS One"},{"key":"B85","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3233\/JAD-130497","article-title":"BDNF, TNFalpha, HSP90, CFH, and IL-10 serum levels in patients with early or late onset Alzheimer\u2019s disease or mild cognitive impairment","volume":"37","author":"Gezen-Ak","year":"2013","journal-title":"J Alzheimers Dis"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.psyneuen.2013.02.006","article-title":"Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer\u2019s disease","volume":"38","author":"Johansson","year":"2013","journal-title":"Psychoneuroendocrinology"},{"key":"B87","doi-asserted-by":"publisher","first-page":"e227","DOI":"10.1038\/tp.2013.11","article-title":"Soluble amyloid precursor protein beta as blood-based biomarker of Alzheimer\u2019s disease","volume":"3","author":"Perneczky","year":"2013","journal-title":"Transl Psychiatry"},{"key":"B88","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3233\/JAD-130392","article-title":"Exploring the value of plasma BIN1 as a potential biomarker for Alzheimer\u2019s disease","volume":"37","author":"Sun","year":"2013","journal-title":"J Alzheimers Dis"},{"key":"B89","doi-asserted-by":"publisher","first-page":"855","DOI":"10.3233\/JAD-140111","article-title":"Apolipoprotein C-III is an amyloid-beta-binding protein and an early marker for Alzheimer\u2019s disease","volume":"41","author":"Shih","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"B90","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/1471-2377-14-64","article-title":"Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer\u2019s disease: an observational study","volume":"14","author":"Hertze","year":"2014","journal-title":"BMC Neurol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1477-5956-12-5","article-title":"Plasma protein profiling of mild cognitive impairment and Alzheimer\u2019s disease using iTRAQ quantitative proteomics","volume":"12","author":"Song","year":"2014","journal-title":"Proteome Sci"},{"key":"B92","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.npep.2015.05.006","article-title":"Plasma leptin levels and free leptin index in women with Alzheimer\u2019s disease","volume":"52","author":"Baranowska-Bik","year":"2015","journal-title":"Neuropeptides"},{"key":"B93","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1021\/cn5003557","article-title":"Decreased plasma iron in Alzheimer\u2019s disease is due to transferrin desaturation","volume":"6","author":"Hare","year":"2015","journal-title":"ACS Chem Neurosci"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.3233\/JAD-141266","article-title":"Plasma protein profiling of mild cognitive impairment and Alzheimer\u2019s disease across two independent cohorts","volume":"43","author":"Muenchhoff","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"B95","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3233\/JAD-142409","article-title":"Elevated plasma angiogenesis factors in Alzheimer\u2019s disease","volume":"45","author":"Qin","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"B96","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1093\/brain\/awl279","article-title":"Proteome-based plasma biomarkers for Alzheimer\u2019s disease","volume":"129","author":"Hye","year":"2006","journal-title":"Brain"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/nm1653","article-title":"Classification and prediction of clinical Alzheimer\u2019s diagnosis based on plasma signaling proteins","volume":"13","author":"Ray","year":"2007","journal-title":"Nat Med"},{"key":"B98","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.cyto.2008.08.013","article-title":"Diagnostic utility of APOE, soluble CD40, CD40L, and Abeta1-40 levels in plasma in Alzheimer\u2019s disease","volume":"44","author":"Ait-Ghezala","year":"2008","journal-title":"Cytokine"},{"key":"B99","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/prca.200780101","article-title":"Proteomic identification and early validation of complement 1 inhibitor and pigment epithelium-derived factor: two novel biomarkers of Alzheimer\u2019s disease in human plasma","volume":"2","author":"Cutler","year":"2008","journal-title":"Proteomics Clin Appl"},{"key":"B100","doi-asserted-by":"publisher","first-page":"e3111","DOI":"10.1371\/journal.pone.0003111","article-title":"Identification of a 5-protein biomarker molecular signature for predicting Alzheimer\u2019s disease","volume":"3","author":"Gomez Ravetti","year":"2008","journal-title":"PLoS One"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1001\/archneurol.2010.215","article-title":"A serum protein-based algorithm for the detection of Alzheimer disease","volume":"67","author":"O\u2019Bryant","year":"2010","journal-title":"Arch Neurol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1017\/S1461145711000459","article-title":"Identification of a blood-based biomarker panel for classification of Alzheimer\u2019s disease","volume":"14","author":"Laske","year":"2011","journal-title":"Int J Neuropsychopharmacol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.neurobiolaging.2009.03.011","article-title":"Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer\u2019s disease","volume":"32","author":"Marksteiner","year":"2011","journal-title":"Neurobiol Aging"},{"key":"B104","doi-asserted-by":"publisher","first-page":"e28092","DOI":"10.1371\/journal.pone.0028092","article-title":"A blood-based screening tool for Alzheimer\u2019s disease that spans serum and plasma: findings from TARC and ADNI","volume":"6","author":"O\u2019Bryant","year":"2011","journal-title":"PLoS One"},{"key":"B105","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000330750","article-title":"A blood-based algorithm for the detection of Alzheimer\u2019s disease","volume":"32","author":"O\u2019Bryant","year":"2011","journal-title":"Dement Geriatr Cogn Disord"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1001\/archneurol.2012.1282","article-title":"Blood-based protein biomarkers for diagnosis of Alzheimer disease","volume":"69","author":"Doecke","year":"2012","journal-title":"Arch Neurol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1212\/WNL.0b013e318266fa70","article-title":"Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease","volume":"79","author":"Hu","year":"2012","journal-title":"Neurology"},{"key":"B108","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1001\/archneurol.2012.1070","article-title":"Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease","volume":"69","author":"Soares","year":"2012","journal-title":"Arch Neurol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/WAD.0b013e31827b60d2","article-title":"Plasma proteomics for the identification of Alzheimer disease","volume":"27","author":"Guo","year":"2013","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"B110","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.jocn.2012.06.005","article-title":"Decreased plasma levels of soluble low density lipoprotein receptor-related protein-1 (sLRP) and the soluble form of the receptor for advanced glycation end products (sRAGE) in the clinical diagnosis of Alzheimer\u2019s disease","volume":"20","author":"Liang","year":"2013","journal-title":"J Clin Neurosci"},{"key":"B111","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/WAD.0b013e31826d597a","article-title":"Evaluation of plasma proteomic data for Alzheimer disease state classification and for the prediction of progression from mild cognitive impairment to Alzheimer disease","volume":"27","author":"Llano","year":"2013","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"B112","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.neulet.2013.03.007","article-title":"Combination of plasma tumor necrosis factor receptors signaling proteins, beta-amyloid and apolipoprotein E for the detection of Alzheimer\u2019s disease","volume":"541","author":"Zhang","year":"2013","journal-title":"Neurosci Lett"},{"key":"B113","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.exger.2013.12.001","article-title":"Analysis of 27 vascular-related proteins reveals that NT-proBNP is a potential biomarker for Alzheimer\u2019s disease and mild cognitive impairment: a pilot-study","volume":"50","author":"Marksteiner","year":"2014","journal-title":"Exp Gerontol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1093\/bioinformatics\/btv173","article-title":"Identification of a small set of plasma signalling proteins using neural network for prediction of Alzheimer\u2019s disease","volume":"31","author":"Agarwal","year":"2015","journal-title":"Bioinformatics"},{"key":"B115","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3389\/fneur.2015.00181","article-title":"Central nervous system and peripheral inflammatory processes in Alzheimer\u2019s disease: biomarker profiling approach","volume":"6","author":"Delaby","year":"2015","journal-title":"Front Neurol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.neulet.2015.04.014","article-title":"Plasma gelsolin and matrix metalloproteinase 3 as potential biomarkers for Alzheimer disease","volume":"595","author":"Peng","year":"2015","journal-title":"Neurosci Lett"},{"key":"B117","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.dadm.2015.04.003","article-title":"Amyloid-\u03b2 sequester proteins as blood-based biomarkers of cognitive decline","volume":"1","author":"Uchida","year":"2015","journal-title":"Alzheimers Dement"},{"key":"B118","doi-asserted-by":"publisher","first-page":"549","DOI":"10.3233\/JAD-141149","article-title":"A candidate plasma protein classifier to identify Alzheimer\u2019s disease","volume":"43","author":"Zhao","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"B119","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1002\/elps.201200360","article-title":"Use of proteomic methods in the analysis of human body fluids in Alzheimer research","volume":"33","author":"Zurbig","year":"2012","journal-title":"Electrophoresis"},{"issue":"1\u2013102","key":"B120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pneurobio.2012.06.007","article-title":"Blood and plasma-based proteomic biomarker research in Alzheimer\u2019s disease","volume":"10","author":"Lista","year":"2013","journal-title":"Prog Neurobiol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/j.1749-6632.2009.05066.x","article-title":"Identifying early markers of Alzheimer\u2019s disease using quantitative multiplex proteomic immunoassay panels","volume":"1180","author":"Soares","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"B122","doi-asserted-by":"publisher","first-page":"e29868","DOI":"10.1371\/journal.pone.0029868","article-title":"Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer\u2019s disease","volume":"7","author":"Bjorkqvist","year":"2012","journal-title":"PLoS One"},{"key":"B123","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3233\/JAD-132102","article-title":"Prognostic polypeptide blood plasma biomarkers of Alzheimer\u2019s disease progression","volume":"40","author":"Yang","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"B124","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.jalz.2014.05.1749","article-title":"Plasma proteins predict conversion to dementia from prodromal disease","volume":"10","author":"Hye","year":"2014","journal-title":"Alzheimers Dement"},{"key":"B125","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1212\/WNL.0000000000001231","article-title":"Brain amyloidosis ascertainment from cognitive, imaging, and peripheral blood protein measures","volume":"84","author":"Apostolova","year":"2015","journal-title":"Neurology"},{"key":"B126","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Doody","year":"2014","journal-title":"N Engl J Med"},{"key":"B127","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N Engl J Med"},{"key":"B128","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1001\/archgenpsychiatry.2010.78","article-title":"Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease","volume":"67","author":"Thambisetty","year":"2010","journal-title":"Arch Gen Psychiatry"},{"key":"B129","doi-asserted-by":"publisher","first-page":"e28527","DOI":"10.1371\/journal.pone.0028527","article-title":"Plasma biomarkers of brain atrophy in Alzheimer\u2019s disease","volume":"6","author":"Thambisetty","year":"2011","journal-title":"PLoS One"},{"key":"B130","doi-asserted-by":"publisher","first-page":"e34078","DOI":"10.1371\/journal.pone.0034078","article-title":"Plasma apolipoprotein levels are associated with cognitive status and decline in a community cohort of older individuals","volume":"7","author":"Song","year":"2012","journal-title":"PLoS One"},{"key":"B131","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.neuroimage.2011.07.056","article-title":"Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment","volume":"59","author":"Thambisetty","year":"2012","journal-title":"Neuroimage"},{"key":"B132","doi-asserted-by":"publisher","first-page":"e64971","DOI":"10.1371\/journal.pone.0064971","article-title":"Inflammatory proteins in plasma are associated with severity of Alzheimer\u2019s disease","volume":"8","author":"Leung","year":"2013","journal-title":"PLoS One"},{"key":"B133","doi-asserted-by":"publisher","first-page":"e55531","DOI":"10.1371\/journal.pone.0055531","article-title":"Relationship between plasma analytes and SPARE-AD defined brain atrophy patterns in ADNI","volume":"8","author":"Toledo","year":"2013","journal-title":"PLoS One"},{"key":"B134","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.jalz.2013.09.016","article-title":"Alzheimer\u2019s disease biomarker discovery using SOMAscan multiplexed protein technology","volume":"10","author":"Sattlecker","year":"2014","journal-title":"Alzheimers Dement"},{"key":"B135","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1159\/000368982","article-title":"Low plasma ApoE levels are associated with smaller hippocampal size in the Alzheimer\u2019s disease neuroimaging initiative cohort","volume":"39","author":"Teng","year":"2015","journal-title":"Dement Geriatr Cogn Disord"},{"key":"B136","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3233\/JAD-2011-110611","article-title":"Plasma transthyretin as a candidate marker for Alzheimer\u2019s disease","volume":"28","author":"Velayudhan","year":"2012","journal-title":"J Alzheimers Dis"},{"key":"B137","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.3233\/JAD-2010-101350","article-title":"Proteome-based plasma markers of brain amyloid-beta deposition in non-demented older individuals","volume":"22","author":"Thambisetty","year":"2010","journal-title":"J Alzheimers Dis"},{"key":"B138","doi-asserted-by":"publisher","first-page":"e44260","DOI":"10.1371\/journal.pone.0044260","article-title":"Plasma based markers of [11C] PiB-PET brain amyloid burden","volume":"7","author":"Kiddle","year":"2012","journal-title":"PLoS One"},{"key":"B139","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/mp.2013.40","article-title":"A blood-based predictor for neocortical Abeta burden in Alzheimer\u2019s disease: results from the AIBL study","volume":"19","author":"Burnham","year":"2014","journal-title":"Mol Psychiatry"},{"key":"B140","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.dadm.2014.11.005","article-title":"Blood protein predictors of brain amyloid for enrichment in clinical trials?","volume":"1","author":"Ashton","year":"2015","journal-title":"Alzheimers Dement (Amst)"},{"key":"B141","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.dadm.2015.01.005","article-title":"Plasma BDNF levels associate with Pittsburgh compound B binding in the brain","volume":"1","author":"Hwang","year":"2015","journal-title":"Alzheimers Dement (Amst)"},{"key":"B142","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3233\/JAD-150020","article-title":"Blood protein markers of neocortical amyloid-beta burden: a candidate study using SOMAscan technology","volume":"46","author":"Voyle","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"B143","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1749-6632.2009.05064.x","article-title":"AddNeuroMed \u2013 the European collaboration for the discovery of novel biomarkers for Alzheimer\u2019s disease","volume":"1180","author":"Lovestone","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"B144","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1093\/cercor\/10.5.464","article-title":"One-year age changes in MRI brain volumes in older adults","volume":"10","author":"Resnick","year":"2000","journal-title":"Cereb Cortex"},{"key":"B145","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.3233\/JAD-150036","article-title":"Clusterin levels in plasma predict cognitive decline and progression to Alzheimer\u2019s disease","volume":"46","author":"Jongbloed","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"B146","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1039\/B712728F","article-title":"Potential roles of abundant extracellular chaperones in the control of amyloid formation and toxicity","volume":"4","author":"Wilson","year":"2008","journal-title":"Mol Biosyst"},{"key":"B147","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0896-6273(03)00850-X","article-title":"ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo","volume":"41","author":"DeMattos","year":"2004","journal-title":"Neuron"},{"key":"B148","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1096\/fj.06-7986com","article-title":"The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures","volume":"21","author":"Yerbury","year":"2007","journal-title":"FASEB J"},{"key":"B149","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.brainresrev.2009.05.007","article-title":"Clusterin: a forgotten player in Alzheimer\u2019s disease","volume":"61","author":"Nuutinen","year":"2009","journal-title":"Brain Res Rev"},{"key":"B150","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/s12035-012-8237-1","article-title":"The role of clusterin in Alzheimer\u2019s disease: pathways, pathogenesis, and therapy","volume":"45","author":"Yu","year":"2012","journal-title":"Mol Neurobiol"},{"key":"B151","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s12264-013-1391-2","article-title":"Clusterin in Alzheimer\u2019s disease: a player in the biological behavior of amyloid-beta","volume":"30","author":"Li","year":"2014","journal-title":"Neurosci Bull"},{"key":"B152","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/mp.2012.163","article-title":"Clusterin regulates beta-amyloid toxicity via Dickkopf-1-driven induction of the wnt-PCP-JNK pathway","volume":"19","author":"Killick","year":"2014","journal-title":"Mol Psychiatry"},{"key":"B153","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/ng1009-1156d","article-title":"Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer\u2019s disease","volume":"41","author":"Harold","year":"2009","journal-title":"Nat Genet"},{"key":"B154","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1038\/ng.439","article-title":"Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer\u2019s disease","volume":"41","author":"Lambert","year":"2009","journal-title":"Nat Genet"},{"key":"B155","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.biopsych.2012.05.026","article-title":"Alzheimer risk variant CLU and brain function during aging","volume":"73","author":"Thambisetty","year":"2013","journal-title":"Biol Psychiatry"},{"key":"B156","doi-asserted-by":"publisher","first-page":"6537","DOI":"10.1523\/JNEUROSCI.5236-13.2014","article-title":"Combined effects of Alzheimer risk variants in the CLU and ApoE genes on ventricular expansion patterns in the elderly","volume":"34","author":"Roussotte","year":"2014","journal-title":"J Neurosci"},{"key":"B157","doi-asserted-by":"publisher","first-page":"36958","DOI":"10.1074\/jbc.M110.127829","article-title":"Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease","volume":"285","author":"Lewis","year":"2010","journal-title":"J Biol Chem"},{"key":"B158","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1586\/14789450.2014.901892","article-title":"The role of apolipoprotein E in neurodegeneration and cardiovascular disease","volume":"11","author":"Lopez","year":"2014","journal-title":"Expert Rev Proteomics"},{"key":"B159","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0197-4580(00)00124-X","article-title":"Inflammation and Alzheimer\u2019s disease","volume":"21","author":"Akiyama","year":"2000","journal-title":"Neurobiol Aging"},{"key":"B160","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3233\/JAD-2005-8406","article-title":"Potential inflammatory biomarkers in Alzheimer\u2019s disease","volume":"8","author":"Mrak","year":"2005","journal-title":"J Alzheimers Dis"},{"key":"B161","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1017\/S1041610209009405","article-title":"The Australian imaging, biomarkers and lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer\u2019s disease","volume":"21","author":"Ellis","year":"2009","journal-title":"Int Psychogeriatr"},{"key":"B162","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1111\/j.1471-4159.2006.04426.x","article-title":"A beta oligomers \u2013 a decade of discovery","volume":"101","author":"Walsh","year":"2007","journal-title":"J Neurochem"},{"key":"B163","first-page":"2311","article-title":"Relationships among local functional activity, energy metabolism, and blood flow in the central nervous system","volume":"40","author":"Sokoloff","year":"1981","journal-title":"Fed Proc"},{"key":"B164","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2967\/jnumed.111.096578","article-title":"Effectiveness and safety of 18F-FDG PET in the evaluation of dementia: a review of the recent literature","volume":"53","author":"Bohnen","year":"2012","journal-title":"J Nucl Med"},{"key":"B165","doi-asserted-by":"publisher","first-page":"390","DOI":"10.2967\/jnumed.107.045385","article-title":"Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer\u2019s disease, and other dementias","volume":"49","author":"Mosconi","year":"2008","journal-title":"J Nucl Med"},{"key":"B166","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s00259-009-1218-6","article-title":"Mapping brain morphological and functional conversion patterns in amnestic MCI: a voxel-based MRI and FDG-PET study","volume":"37","author":"Morbelli","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B167","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.nicl.2014.03.005","article-title":"Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer\u2019s pathology","volume":"4","author":"Laforce","year":"2014","journal-title":"Neuroimage Clin"},{"key":"B168","doi-asserted-by":"publisher","first-page":"143","DOI":"10.4172\/2161-0460.1000143","article-title":"Imaging brain metabolism and pathology in Alzheimer\u2019s disease with positron emission tomography","volume":"4","author":"Shokouhi","year":"2014","journal-title":"J Alzheimers Dis Parkinsonism"},{"key":"B169","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1093\/brain\/awr038","article-title":"18F-THK523: a novel in vivo tau imaging ligand for Alzheimer\u2019s disease","volume":"134","author":"Fodero-Tavoletti","year":"2011","journal-title":"Brain"},{"key":"B170","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3233\/JAD-122059","article-title":"Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807","volume":"34","author":"Chien","year":"2013","journal-title":"J Alzheimers Dis"},{"key":"B171","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3233\/JAD-130098","article-title":"Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808","volume":"38","author":"Chien","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"B172","doi-asserted-by":"publisher","first-page":"e21643","DOI":"10.1371\/journal.pone.0021643","article-title":"Metabolomics in early Alzheimer\u2019s disease: identification of altered plasma sphingolipidome using shotgun lipidomics","volume":"6","author":"Han","year":"2011","journal-title":"PLoS One"},{"key":"B173","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1002\/elps.201400196","article-title":"Metabolomic profiling of serum in the progression of Alzheimer\u2019s disease by capillary electrophoresis-mass spectrometry","volume":"35","author":"Gonzalez-Dominguez","year":"2014","journal-title":"Electrophoresis"},{"key":"B174","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nm.3466","article-title":"Plasma phospholipids identify antecedent memory impairment in older adults","volume":"20","author":"Mapstone","year":"2014","journal-title":"Nat Med"},{"key":"B175","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.neurobiolaging.2013.08.001","article-title":"Evidence of altered phosphatidylcholine metabolism in Alzheimer\u2019s disease","volume":"35","author":"Whiley","year":"2014","journal-title":"Neurobiol Aging"},{"key":"B176","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3233\/JAD-121501","article-title":"Blood transcriptomic biomarkers of Alzheimer\u2019s disease patients treated with EHT 0202","volume":"34","author":"Desire","year":"2013","journal-title":"J Alzheimers Dis"},{"key":"B177","doi-asserted-by":"publisher","first-page":"737","DOI":"10.3233\/JAD-2012-121363","article-title":"A blood gene expression marker of early Alzheimer\u2019s disease","volume":"33","author":"Lunnon","year":"2013","journal-title":"J Alzheimers Dis"}],"container-title":["Frontiers in Neurology"],"original-title":[],"deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T19:43:05Z","timestamp":1498246985000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/Article\/10.3389\/fneur.2015.00236\/abstract"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,16]]},"references-count":177,"URL":"https:\/\/doi.org\/10.3389\/fneur.2015.00236","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,16]]}}}